The relevance of IL-22 in AD pathogenesis was evidenced in phase 2 clinical trials using a neutralizing anti-IL-22 monoclonal antibody (Fezakinumab), which resulted in progressive and sustained clinical improvements in adult patients with moderate or severe AD [7]. The gene discussed is IL22; the disease is Alzheimer disease.